Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Am J Med Genet ; 44(6): 816-21, 1992 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-1481854

RESUMO

Several organizations have proposed guidelines for fra(X) studies on peripheral blood lymphocytes. To evaluate these guidelines, we reviewed 1,033 consecutive specimens referred for fra(X) analysis. Each specimen was cultured with medium 199 and RPMI 1640 with 5-fluorodeoxyuridine or excess thymidine. The karyotype and expression of fra(X) were established from 20 GTL- or QFQ-banded cells and by screening of up to 130 more banded cells. We found anomalies other than fra(X) in 37 (3.6%) of the patients. We found 4% or more fra(X) cells in 38 (3.7%) cases from 36 unrelated families, including 33 (3.9%) of 850 males and 5 (2.7%) of 183 females. Another 4 females had 1 to 3% fra(X) cells. Six specimens were fra(X)-positive in only one stress system, and 32 were positive in 2 systems. To find the first 2 fra(X) cells in males, we needed to study up to 36 cells in 31 cases, 50 in one case, and 57 in another. To find the first 2 fra(X) cells in females, we needed to study up to 17 cells in 4 cases and 57 in another. A strong family history of fra(X) occurred in 5 patients, and each one was fra(X)-positive. Some manifestations of the fragile X syndrome occurred in 507 cases, 17 (3%) of which were fra(X)-positive. Abnormalities considered unlikely to be the fragile X syndrome occurred in 103 cases, 3 (3%) of which were fra(X)-positive. Use of chromosome breakage and fra(3)(p14) as quality control indicators of the fra(X) stress systems was found to be unreliable.(ABSTRACT TRUNCATED AT 250 WORDS)


Assuntos
Citogenética/métodos , Testes Diagnósticos de Rotina , Síndrome do Cromossomo X Frágil/diagnóstico , Linfócitos/ultraestrutura , Adolescente , Adulto , Contagem de Células , Células Cultivadas , Criança , Pré-Escolar , Aberrações Cromossômicas , Meios de Cultura , Citogenética/normas , Testes Diagnósticos de Rotina/economia , Testes Diagnósticos de Rotina/métodos , Testes Diagnósticos de Rotina/normas , Feminino , Floxuridina/farmacologia , Ácido Fólico/administração & dosagem , Síndrome do Cromossomo X Frágil/genética , Síndrome do Cromossomo X Frágil/patologia , Testes Genéticos , Humanos , Lactente , Recém-Nascido , Cariotipagem , Linfócitos/efeitos dos fármacos , Masculino , Metáfase , Pessoa de Meia-Idade , Guias de Prática Clínica como Assunto , Garantia da Qualidade dos Cuidados de Saúde , Estudos Retrospectivos , Timidina/farmacologia
2.
Am J Med Genet ; 46(4): 441-3, 1993 Jun 01.
Artigo em Inglês | MEDLINE | ID: mdl-8357018

RESUMO

Myotonic dystrophy (DM) is an autosomal dominant disorder characterized by a trinucleotide (AGC) amplification at 19q13.3. The degree of trinucleotide amplification may increase in successive generations and generally correlates with severity of the disorder. Because amplification of a trinucleotide repeat is also associated with the observation of a fra(X)(q27.3) in the fragile X syndrome, we investigated whether chromosome fragility at 19q13.3 might be inducible in patients with DM. Using 3 different culture stress systems (medium 199, RPMI 1640 with excess TdR, and RPMI 1640 with FudR) and high resolution chromosome analyses, we studied 6 individuals with DM and 5 unaffected relatives representing two unrelated families. Molecular studies were done on two of the most affected patients and showed AGC repeat sequences of 970 and 1,260 at 19q13.3. The normal range of AGC repeat is 5 to 30. We found no indication of fragility at 19q13.3 in any of these individuals.


Assuntos
Fragilidade Cromossômica , Cromossomos Humanos Par 19 , Síndrome do Cromossomo X Frágil/genética , Distrofia Miotônica/genética , Adolescente , Adulto , Humanos , Lactente , Cariotipagem , Pessoa de Meia-Idade
3.
Gut ; 55(2): 197-204, 2006 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-16407385

RESUMO

BACKGROUND AND AIMS: Intralumenal bile acid (BA) concentrations have a profound effect on cholesterol absorption. We performed studies to assess the effects of markedly reduced lumenal BA on cholesterol absorption in children with inborn errors in BA synthesis and the role of micellar solubilisation of cholesterol on its absorption in an animal model using human intestinal contents. METHODS: We studied five subjects: two with 3beta hydroxy-C27 steroid dehydrogenase isomerase deficiency (3-HSD), two with Delta(4)-3-oxosteroid 5beta reductase deficiency (5beta reductase), and one with 2-methylacyl CoA racemase deficiency (racemase). Subjects were studied on supplemental BA therapy and three weeks after withdrawal of supplements. During each treatment period a liquid meal was consumed. Duodenal samples were collected and analysed, and cholesterol absorption and cholesterol fractional synthetic rates were measured. Human intralumenal contents were infused in a bile diverted rat lymph fistula model to assess micellar versus vesicular absorption of cholesterol. RESULTS: Without BA supplementation, intralumenal BA concentrations were below the critical micellar concentration (CMC) whereas intralumenal BAs increased to above the CMC in all subjects on BA supplementation. Lumenal cholesterol was carried primarily as vesicles in untreated subjects whereas it was carried as both micelles and vesicles in treated subjects. Cholesterol absorption increased approximately 55% in treated compared with untreated subjects (p=0.041), with a simultaneous 70% decrease in synthesis rates (p=0.029). In the rat lymph fistula model, minimal vesicular cholesterol was absorbed whereas vesicular and micellar fatty acid and phospholipid were comparably absorbed. CONCLUSIONS: Increasing micellar cholesterol solubilisation by supplemental BA in subjects with inborn errors of BA synthesis leads to an improvement in cholesterol absorption and reduction in cholesterol synthesis due to improved micellar solubilisation of cholesterol.


Assuntos
Ácidos e Sais Biliares/biossíntese , Colesterol/farmacocinética , Erros Inatos do Metabolismo de Esteroides/metabolismo , 3-Hidroxiesteroide Desidrogenases/deficiência , Adolescente , Adulto , Animais , Ácidos e Sais Biliares/metabolismo , Ácidos e Sais Biliares/uso terapêutico , Criança , Colesterol/administração & dosagem , Colesterol/biossíntese , Duodeno/metabolismo , Feminino , Humanos , Absorção Intestinal , Linfa/metabolismo , Masculino , Micelas , Oxirredutases/deficiência , Racemases e Epimerases/deficiência , Ratos , Ratos Sprague-Dawley , Solubilidade , Erros Inatos do Metabolismo de Esteroides/fisiopatologia , Erros Inatos do Metabolismo de Esteroides/terapia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA